Wednesday, March 06, 2024 4:58:06 PM
Recent NXL News
- Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements • GlobeNewswire Inc. • 04/25/2024 02:44:22 PM
- Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device • GlobeNewswire Inc. • 04/04/2024 05:00:00 PM
- Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board • GlobeNewswire Inc. • 04/02/2024 12:30:00 PM
- Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device • GlobeNewswire Inc. • 02/08/2024 01:30:00 PM
- Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System • GlobeNewswire Inc. • 01/23/2024 01:30:00 PM
- Nexalin Technology Unveils Next-Generation HALO™ Clarity • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression • GlobeNewswire Inc. • 12/18/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:38:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 07:38:03 PM
- Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures • GlobeNewswire Inc. • 10/16/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 04:09:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 04:08:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 04:07:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 08:18:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 07:07:19 PM
- Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms • GlobeNewswire Inc. • 08/07/2023 12:30:00 PM
- Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time • GlobeNewswire Inc. • 08/03/2023 12:30:00 PM
- Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies • GlobeNewswire Inc. • 07/26/2023 12:30:00 PM
- Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury • GlobeNewswire Inc. • 07/10/2023 12:30:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/30/2023 07:15:44 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM